BrightSpring Health Services (BTSG) recently raised its 2026 revenue guidance and outlined a stronger EBITDA growth outlook, putting its specialty therapies and home-based care expansion in sharper focus for investors tracking healthcare platforms.
BrightSpring Health Services has drawn more attention as the share price climbed to US$56.76, with a 1-day share price return of 1.92% and a year-to-date share price return of 47.81%. The 1-year total shareholder return of 90.21% signals strong longer term momentum despite a 90-day share price return that declined 17.77%, suggesting recent weakness may be viewed as a reset after a powerful run linked to its updated 2026 guidance narrative.
Scan other healthcare platforms showing similar momentum and guidance resets by running the curated 32 high quality undervalued stocks alongside BrightSpring Health Services for comparison.
Bulls see BrightSpring Health Services as a high growth healthcare platform on sale after a sharp pullback. Bears see guidance optimism already reflected. Which story does the current valuation actually support next?
Most Popular Narrative: 20% Undervalued
BrightSpring Health Services is framed as undervalued in the leading narrative, with a fair value of $70.59 versus the recent close at $56.76. That gap anchors a thesis that leans heavily on how this business earns its money rather than on headline home health exposure.
The real business is not home health. It is pharmacy.
Roughly 80% of revenue comes from specialty and institutional pharmacy services:
• Infusion therapies delivered at home (oncology, autoimmune, IV antibiotics)
• Long-term care pharmacy services in assisted living and nursing facilities
• Specialty drug distribution for chronic and rare disease patients
This is where the structural moat exists:
Patients are not “customers” in the retail sense, they are clinically managed cases. Once a patient enters an infusion or specialty pharmacy program, switching providers is rare because:
• Treatment continuity is medically sensitive
• Coordination with nurses and physicians is embedded
• Insurance authorization is complex and sticky
• Logistics (cold chain, dosing schedules) are specialized
This creates low churn, recurring revenue, and embedded payer relationships.
In short, BrightSpring is closer to a healthcare infrastructure platform than a traditional pharmacy company.
See why 8 investors see BrightSpring Health Services as 20% undervalued.
Result: Fair Value of $70.59 (UNDERVALUED)
Still, BrightSpring Health Services relies heavily on U.S. government reimbursement, and any pressure on specialty pharmacy economics or home-based care funding could quickly undercut this bullish setup.
Find out about the key risks to this BrightSpring Health Services narrative.
Next Steps
Plenty of investors view BrightSpring Health Services through either a risk-first lens or a reward-first lens, so move quickly, review the details, and decide where you stand by checking the 4 key rewards and 1 important warning sign.
Looking for more BrightSpring Health Services style ideas?
If you are serious about sharpening your watchlist beyond BrightSpring Health Services, use the Simply Wall Street Screener now so you are not reacting after the next move.
- Target robust cash generators that the market may be overlooking by running the 18 high quality undiscovered gems.
- Prioritise balance sheet strength and financial resilience by scanning the list of solid balance sheet and fundamentals (25 results).
- Dial down portfolio risk by focusing on companies that pass the 31 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com